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Amid the feverish pace of biomedical
research in the United States and abroad,
one might assume that scientists are fast ap-
proaching cures for every disease affecting
mankind.  The  U.S.  federal  government
alone funds more than $30 billion annually
to biomedical research, which is distributed
through the National Institutes of Health
(NIH†) [1]. However, cures for all human
diseases remain more of a dream than real-
ity ― of the 4,400 conditions with known
molecular causes, treatments are only avail-
able for 250 [2]. To increase the pace of de-
veloping clinically relevant diagnostics and
therapeutics, the NIH recently underwent a
sweeping restructuring to establish the Na-
tional Center for Advancing Translational
Sciences (NCATS) [1]. Ultimately, the goal
of translational medicine is to reduce the
time from identifying the molecular causes
of a disease to designing an effective diag-
nostic or treatment. 
Yale University has been at the fore-
front of translational research efforts. As
one of the original awardees of the NIH’s
Clinical and Translational Science Awards
(CTSA), the Yale School of Medicine es-
tablished the Yale Center for Clinical In-
vestigation in 2006 [3]. The mission of the
Center is both to train the next generation
of translational clinicians and scientists and
to promote translational research. This past
year, Yale was one of three institutions in
the United States to receive funding from
the  NIH  for  the  study  of  rare  diseases,
which collectively affects the lives of more
than 25 million Americans [4]. 
In light of the growing emphasis on
clinically relevant biomedical research, the
Yale Journal of Biology and Medicine pres-
ents a special section on translational med-
icine. The reviews highlight the various
stages of going from “bench to bedside”
and the implications faced by clinicians,
scientists, and patients. 
On the basic research side of the spec-
trum, Clark and colleagues review recent
advances in the understanding of dengue
virus. The authors discuss the existence of
alternative viral morphologies of dengue
virus, which may facilitate the development
of medical interventions for dengue virus
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give an overview of the LDL receptor fam-
ily, focusing on the lesser-known members
and their recently discovered role in hyper-
lipidemia and atherosclerosis. These articles
highlight the importance of basic research as
a jumping-off point for future clinical treat-
ments.
Further along the spectrum toward the
clinical side, Fendos and Engelman articulate
how a well-known biomarker for many can-
cers, localized cellular acidity, can be ex-
ploited  for  tumor  identification  with  a
pH-dependent peptide, pHLIP. In diabetes-re-
lated research, Jamiolkowski and colleagues
revisit pancreatic islet transplantation, a con-
troversial type I diabetes mellitus therapy, as
a potentially promising treatment for patients.  
We often think of translational research
and  drug  discovery  as  a  one-way  street,
starting with the identification of a molecu-
lar mechanism and eventually leading to a
drug that can specifically target a component
of the pathway. However, drugs often have
unexpected effects, which can lead to the
discovery of unknown pathways. Here, Arn-
sten and Jin provide a historical review of
the discovery of Guanfacine and its unex-
pected effects in the prefrontal cortex, which
ultimately led to its use as a treatment for
cognitive disorders.  
Additionally, cutting-edge advances in
medical technology can lead to improve-
ments in patient care. Paulo and colleagues
provide a technical review on modern pep-
tide mass spectrometry and discuss the fu-
ture of these techniques in the discovery of
clinically relevant biomarkers. Stacy, Max-
field, and Sinusas review recent advances
in the imaging techniques of positron emis-
sion tomography (PET) and single photon
emission tomography (SPECT), particularly
as  they  relate  to  cardiovascular  disease.
Rapidly developing fields, such as personal
genomics, can have far-reaching implica-
tions for patients, clinicians, and society at
large. Kung and Gelbart highlight the im-
portance of genetic education in light of
personal genome sequencing. Additionally,
they offer perspective on issues associated
with genetics education and describe their
experiences developing the Personal Ge-
netics Education Project at Harvard Med-
ical School.
We hope these articles offer a glimpse
into  both  the  scientific  complexities  and
clinical  challenges  faced  in  translational
medicine. Additionally, we must consider
how advancing technologies, such as per-
sonal genomic sequencing, may affect indi-
viduals  and  society.  As  the  urgency  of
developing novel diagnostics and treatments
remains,  the  renewed  focus  by  the  NIH
marks the beginning of an exciting era in
translational medicine.
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